Literature DB >> 9199444

Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes.

M F Rocha1, M E Maia, L R Bezerra, D M Lyerly, R L Guerrant, R A Ribeiro, A A Lima.   

Abstract

Clostridium difficile produces a potent enterotoxin and cytotoxin, toxins A and B, respectively, which appear to be responsible for pseudomenbranous colitis and antibiotic-associated diarrhea. In the present study we explored the neutrophil migration evoked by toxin A in the peritoneal cavities and subcutaneous air pouches of rats and examined the role of macrophages and their inflammatory mediators in this process. Toxin A causes a significant dose-dependent neutrophil influx into the peritoneal cavity, with a maximal response at 0.1 microg/ml and at 4 h. The depletion of macrophages by peritoneal washing prevents the toxin A-induced neutrophil migration into the peritoneal cavity. In contrast, an increase in macrophages induced by peritoneal injection of thioglycolate amplifies this toxin effect on neutrophil migration. Furthermore, the injection of supernatants from toxin A-stimulated macrophages into the rat peritoneal cavity causes significant neutrophil migration. Pretreatment of rats with BWA4C, nordihydroguaiaretic acid, mepacrine, or dexamethasone inhibits the neutrophil migration evoked by toxin A in the peritoneal cavities. However, pretreatment with the cyclooxygenase inhibitor indomethacin or the platelet-activating factor antagonist BN52021 fails to alter toxin A-induced neutrophil migration. Toxin A was also injected into air pouches of normal rats or rats pretreated with anti-interleukin-1beta (anti-IL-1beta) or anti-tumor necrosis factor alpha (anti-TNF-alpha) antibodies. Anti-TNF-alpha or anti-IL-1beta antibodies significantly reduce the neutrophil migration induced by toxin A. These data suggest that neutrophil migration evoked by toxin A is in part dependent on macrophage-derived cytokines, such as TNF-alpha and IL-1beta, and leukotrienes. These mediators may help to explain the intense inflammatory colitis caused by C. dificile toxin A in an experimental animal model of this disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199444      PMCID: PMC175386          DOI: 10.1128/iai.65.7.2740-2746.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine.

Authors:  M Di Rosa; J P Giroud; D A Willoughby
Journal:  J Pathol       Date:  1971-05       Impact factor: 7.996

2.  Increased inflammatory reactivity in newly formed lining tissue.

Authors:  A D Sedgwick; Y M Sin; J C Edwards; D A Willoughby
Journal:  J Pathol       Date:  1983-12       Impact factor: 7.996

3.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

4.  Purification and characterization of toxins A and B of Clostridium difficile.

Authors:  N M Sullivan; S Pellett; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

5.  The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system.

Authors:  J C Edwards; A D Sedgwick; D A Willoughby
Journal:  J Pathol       Date:  1981-06       Impact factor: 7.996

6.  Chemotactic and mitogenic components of the alveolar macrophage response to particles ad neutrophil chemoattractant.

Authors:  I Y Adamson; D H Bowden
Journal:  Am J Pathol       Date:  1982-10       Impact factor: 4.307

7.  Anti-inflammatory drugs, prostaglandins and leucocyte migration.

Authors:  J R Walker; M J Smith; A W Ford-Hutchinson
Journal:  Agents Actions       Date:  1976-09

8.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

9.  Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum.

Authors:  C Pothoulakis; F Karmeli; C P Kelly; R Eliakim; M A Joshi; C J O'Keane; I Castagliuolo; J T LaMont; D Rachmilewitz
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

10.  Comparison of two toxins produced by Clostridium difficile.

Authors:  N S Taylor; G M Thorne; J G Bartlett
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

View more
  28 in total

1.  Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis.

Authors:  I C Cavalcante; M V Castro; A R F Barreto; G W Sullivan; M Vale; P R C Almeida; J Linden; J M Rieger; F Q Cunha; R L Guerrant; R A Ribeiro; G A C Brito
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Caspase and bid involvement in Clostridium difficile toxin A-induced apoptosis and modulation of toxin A effects by glutamine and alanyl-glutamine in vivo and in vitro.

Authors:  Benedito A Carneiro; Jun Fujii; Gerly A C Brito; Cirle Alcantara; Reinaldo B Oriá; Aldo A M Lima; Tom Obrig; Richard L Guerrant
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Clostridium difficile-induced colitis in mice is independent of leukotrienes.

Authors:  Bruno C Trindade; Casey M Theriot; Jhansi L Leslie; Paul E Carlson; Ingrid L Bergin; Marc Peters-Golden; Vincent B Young; David M Aronoff
Journal:  Anaerobe       Date:  2014-09-16       Impact factor: 3.331

4.  Effects of toxin A from Clostridium difficile on mast cell activation and survival.

Authors:  G M Calderón; J Torres-López; T J Lin; B Chavez; M Hernández; O Muñoz; A D Befus; J A Enciso
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.

Authors:  J A Kink; J A Williams
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

6.  Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.

Authors:  Hua Yu; Kevin Chen; Ying Sun; Mihaela Carter; Kevin W Garey; Tor C Savidge; Sridevi Devaraj; Mary Elizabeth Tessier; Erik C von Rosenvinge; Ciaran P Kelly; Marcela F Pasetti; Hanping Feng
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

7.  Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.

Authors:  Hon Wai Koon; David Q Shih; Tressia C Hing; Jun Hwan Yoo; Samantha Ho; Xinhua Chen; Ciarán P Kelly; Stephan R Targan; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

8.  Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B.

Authors:  Ralf Gerhard; Swenja Queisser; Helma Tatge; Gesa Meyer; Oliver Dittrich-Breiholz; Michael Kracht; Hanping Feng; Ingo Just
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-26       Impact factor: 3.000

Review 9.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 10.  Enteroaggregative Escherichia coli.

Authors:  J P Nataro; T Steiner; R L Guerrant
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.